AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 24389521
Drug: Circuit resistance
RxNorm normalized name: BREATHING CIRCUIT W/MOUTHPIECE,STANDARD
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Circuit resistance training (CRT) performed three times weekly for 40‐45 min each session with immediate protein supplementation (PS) of whey protein = 36‐37 g before and after exercise
Trial: 24389521
Drug: Circuit resistance
RxNorm normalized name: BREATHING CIRCUIT W/MOUTHPIECE,STANDARD
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Circuit resistance training (CRT) performed three times weekly for 40‐45 min each session with delayed protein supplementation (PS) of matched protein dose 24 h postexercise
Trial: 22153143
Drug: Mindfulness training
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Mindfulness training through yoga, 1 hour a week for 8 weeks, plus 10 minutes of daily homework
Trial: 18652112
Drug: Rehabilitation treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rehabilitation treatment only
Trial: 12870876
Drug: 1 mL
RxNorm normalized name: ethanol 1 ML/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mL Oil of Wintergreen
Trial: 12870876
Drug: 6.7 g
RxNorm normalized name: ALCOHOL 16.7 g in 30 mL TOPICAL SPRAY [HS]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6.7 g of Ben Gay 15%
Trial: 12870876
Drug: 20 g
RxNorm normalized name: PEG-20 glyceryl oleate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 g of Ben Gay 15%
Trial: 12870876
Drug: 5 g
RxNorm normalized name: 15 g/31 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 g of Ben Gay 15% cream held in the buccal cavity for 1 minute and then expectorated
Trial: 10554538
Drug: Sodium selenite
RxNorm normalized name: Sodium selenite
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: Sodium selenite i.v. 1 mg bolus/2 x 1 mg infusion 1 day before ERCP
Trial: 10554538
Drug: Metronidazole 0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metronidazole 0.5 g/ofloxacin 0.2 g before and 6 hours after ERCP
Trial: 8919724
Drug: Tetracycline (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tetracycline (500 mg orally every 6 hours for 3 days)
Trial: 8919724
Drug: Co-trimoxazole (160
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Co-trimoxazole (160 mg of trimethoprim and 800 mg of sulfamethoxazole orally every 12 hours for 3 days)
Trial: 16146617
Drug: Doxycycline hyclate
RxNorm normalized name: Doxycycline Hyclate
DrugBank: Doxycycline (DB00254)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Doxycycline hyclate 20 mg bid
Trial: 16146617
Drug: Doxycycline hyclate
RxNorm normalized name: Doxycycline Hyclate
DrugBank: Doxycycline (DB00254)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Doxycycline hyclate 100 mg daily for eight weeks
Trial: 11006368
Drug: Control (no
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (no growth hormone treatment)
Trial: 1360714
Drug: Sulfasalicylic drugs
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sulfasalicylic drugs (SSD)
Trial: 1360714
Drug: Nonsteroidal anti-inflammatory
RxNorm normalized name: Surpass Anti-Inflammatory
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nonsteroidal anti-inflammatory drugs (NSAID)
Trial: 3901360
Drug: 5 grams
RxNorm normalized name: phenylbutyrate
DrugBank: Phenylbutyric acid (DB06819)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 grams of cefamandole in four doses over a period of 18 hours
Trial: 27518403
Drug: IFN-α2b spray
RxNorm normalized name: RAD-IFN-2B
DrugBank: Nadofaragene firadenovec (DB17381)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IFN-α2b spray
Trial: 10096928
Drug: Azithromycin (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Azithromycin (500 mg/d for 3 days, then 500 mg/wk for 3 months)
Trial: 1867419
Drug: Oral atropine
RxNorm normalized name: atropine Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral atropine (0.02 mg/kg)
Trial: 1867419
Drug: Oral glycopyrrolate
RxNorm normalized name: Glycopyrrolate
DrugBank: Glycopyrronium (DB00986)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral glycopyrrolate (0.05 mg/kg)
Trial: 6617931
Drug: 2 g
RxNorm normalized name: Molds 2 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 g of L-carnitine
Trial: 28604135
Drug: SOY+RT (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SOY+RT (25 g of soy protein with resistance training)
Trial: 28604135
Drug: PL+RT (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PL+RT (25 g of maltodextrin placebo with resistance training)
Trial: 27090817
Drug: Casein glycomacropeptide
RxNorm normalized name: caseins
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Casein glycomacropeptide (CGMP) 30 g daily
Trial: 27090817
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment (4800 mg oral mesalamine daily)
Trial: 22792813
Drug: Transfer factor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transfer factor oral liquid, 10 mL, 2 times daily orally, for 2 months
Trial: 12957267
Drug: Vascular brachytherapy
RxNorm normalized name: acellular tissue engineered vessel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vascular brachytherapy (VBT) with a (90)Sr/(90)Y source, prescribed dose at 2 mm from the centerline of the source axis was 18.4 Gy or 23 Gy
Trial: 11106135
Drug: Sertraline-Continuation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sertraline-Continuation
Trial: 6329547
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg enalapril twice daily (n = 18)
Trial: 31272495
Drug: Oral HIVST
RxNorm normalized name: Ala-Hist IR Oral Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral HIVST with biannual clinic visits plus oral HIVSTs
Trial: 31252222
Drug: Biperiden (M1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Biperiden (M1 receptor antagonist, 4 mg)
Trial: 28552878
Drug: LD+MCT (L-leucine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LD+MCT (L-leucine 1.2 g, cholecalciferol 20 μg, 6 g of MCT)
Trial: 28552878
Drug: LD+LCT (L-leucine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LD+LCT (L-leucine 1.2 g, cholecalciferol 20 μg, 6 g of long-chain triglycerides)
Trial: 24330691
Drug: Sildenafil (phosphodiesterase
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sildenafil (phosphodiesterase 5 inhibitor) administered daily for a short term (duration not specified)
Trial: 21554816
Drug: 10 g
RxNorm normalized name: Co Q-10 Gummies
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 g α-cyclodextrin
Trial: 12626865
Drug: Intramuscular pethidine
RxNorm normalized name: pethidine
DrugBank: Meperidine (DB00454)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intramuscular pethidine analgesia
Trial: 8396099
Drug: Azithromycin (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Azithromycin (10 mg/kg/day, single dose for three days)
Trial: 8396099
Drug: Co-amoxiclav (tid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Co-amoxiclav (tid for ten days, dosage according to manufacturer's instructions)
Trial: 3002707
Drug: Omeprazole (60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omeprazole (60 mg daily for 7 days)
Trial: 26948252
Drug: Intravenous frusemide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous frusemide and enteral indapamide (Group F + I)
Trial: 26948252
Drug: Intravenous frusemide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous frusemide (Group F)
Trial: 24499394
Drug: Cognitive-behavioural group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive-behavioural group therapy (CBT)
Trial: 12848392
Drug: Bovine colostrum
RxNorm normalized name: Bovine Colostrum
DrugBank: Bos taurus colostrum (DB19249)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bovine colostrum (60 g x day(-1))
Trial: 10594483
Drug: Fantofarone 100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fantofarone 100 mg
Trial: 10594483
Drug: Fantofarone 300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fantofarone 300 mg
Trial: 8546738
Drug: cM‐T412 monoclonal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: cM‐T412 monoclonal antibody, 50 mg/day for 5 days, followed by 50 mg/week for 5 weeks (6 patients) or retreatment of 50 mg/day for 5 days after 5 weeks (6 patients)
Trial: 1986287
Drug: 3 mg
RxNorm normalized name: boron 3 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 mg of cyclosporine per kilogram per day
Trial: 1986287
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg of cyclosporine per kilogram per day
Trial: 1986287
Drug: 7.5 mg
RxNorm normalized name: biotin 7.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 7.5 mg of cyclosporine per kilogram per day
Trial: 7423283
Drug: PGE2 4.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PGE2 4.5 mg in the form of 0.5 mg oral tablets
Trial: 7423283
Drug: PGE2 4.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PGE2 4.5 mg in the form of tylose gel
Trial: 27734072
Drug: Argatroban therapy
RxNorm normalized name: Argatroban
DrugBank: Argatroban (DB00278)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Argatroban therapy initiated on the same day
Trial: 27734072
Drug: Argatroban therapy
RxNorm normalized name: Argatroban
DrugBank: Argatroban (DB00278)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Argatroban therapy delayed by one or more days
Trial: 25577176
Drug: Intravenous immunoglobulin
RxNorm normalized name: Intravenous immunoglobulin (IVIg)
DrugBank: Human immunoglobulin G (DB00028)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous immunoglobulin (IVIg) administration
Trial: 24772726
Drug: Probiotic formulation
RxNorm normalized name: Rezyst Probiotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Probiotic formulation containing Lactobacillus acidophilus LA-5 and Bifidobacterium BB-12
Trial: 15220012
Drug: Pioglitazone (15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pioglitazone (15 mg QD initially, titrated to max 45 mg)
Trial: 15220012
Drug: Glimepiride (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glimepiride (2 mg QD initially, titrated to max 8 mg)
Trial: 11527474
Drug: rhGH administered
RxNorm normalized name: rhGH
DrugBank: Somatotropin (DB00052)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rhGH administered subcutaneously daily at bedtime
Trial: 11527474
Drug: Structured resistance
RxNorm normalized name: LIPID,STRUCTURED (FROM SUNFLOWER OIL)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Structured resistance exercise with placebo injections
Trial: 11527474
Drug: Placebo injections
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo injections only
Trial: 9239456
Drug: Test patch
RxNorm normalized name: mumps skin test antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Test patch (MenorestTM) at 37.5 micrograms E2/day
Trial: 9239456
Drug: Test patch
RxNorm normalized name: mumps skin test antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Test patch (MenorestTM) at 50 micrograms E2/day
Trial: 9239456
Drug: Test patch
RxNorm normalized name: mumps skin test antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Test patch (MenorestTM) at 75 micrograms E2/day
Trial: 9239456
Drug: Reference patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reference patch at 50 micrograms E2/day
Trial: 3102323
Drug: Sodium cromoglycate
RxNorm normalized name: Sodium cromoglycate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sodium cromoglycate (600 mg/100 ml) by enema
Trial: 3102323
Drug: Prednisolone (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prednisolone (20 mg/100 ml) by enema
Trial: 4932544
Drug: Amantadine hydrochloride
RxNorm normalized name: Amantadine Hydrochloride
DrugBank: Amantadine (DB00915)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Amantadine hydrochloride (200 mg daily)
Trial: 31957417
Drug: 0.2% chlorhexidine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.2% chlorhexidine gel (CG gel)
Trial: 27709225
Drug: Acarbose (20-week
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acarbose (20-week treatment)
Trial: 27709225
Drug: Rosiglitazone (24-week
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rosiglitazone (24-week treatment on top of metformin)
Trial: 22094635
Drug: MenACWY-CRM coadministered
RxNorm normalized name: Meningococcal oligosaccharide (MenACWY), (MenB), PF
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MenACWY-CRM coadministered with routine vaccines
Trial: 17709295
Drug: 1000 mg
RxNorm normalized name: bran 1000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1000 mg levetiracetam
Trial: 17709295
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg topiramate
Trial: 12042580
Drug: Zinc supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zinc supplementation (10 mg for infants and 20 mg for older children)
Trial: 10442852
Drug: Isoprenaline (0.1-0.8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isoprenaline (0.1-0.8 microg/min) with L-NMMA (3.0 mg/kg over 5 min, followed by 30 microg/kg/min over 75 min)
Trial: 10442852
Drug: Isoprenaline (0.1-0.8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isoprenaline (0.1-0.8 microg/min) with L-NMMA (6.0 mg/kg over 5 min, followed by 60 microg/kg/min over 75 min)
Trial: 8674563
Drug: 1.2 g
RxNorm normalized name: Humidifier 1.2 gallon
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.2 g of Augmentin (co‐amoxiclav) i.v. at induction of anaesthesia
Trial: 2190041
Drug: Verapamil, 320
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Verapamil, 320 mg/day
Trial: 2190041
Drug: Ethmosine, 800
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ethmosine, 800 mg/day
Trial: 2190041
Drug: Ethacizine, 150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ethacizine, 150 mg/day
Trial: 32799
Drug: Lormetazepam (0.5,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lormetazepam (0.5, 1, 2, 4, 8 mg)
Trial: 32799
Drug: Pentobarbital (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pentobarbital (100 mg)
Trial: 30916575
Drug: Human milk
RxNorm normalized name: HUMAN MILK
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Human milk (Prolacta Bioscience, Duarte, CA) administered from day -3 until day +14 after BMT
Trial: 24276097
Drug: Negative-pressure wound
RxNorm normalized name: Microcyn Negative-Pressure Wound
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Negative-pressure wound therapy (NPWT) applied to open fractures in the 2008-2009 cohort.
Trial: 19731848
Drug: Inhalation of
RxNorm normalized name: Ocean brand of sodium chloride Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhalation of 70% isopropyl alcohol (IPA)
Trial: 17909211
Drug: Tricyclic antidepressants
RxNorm normalized name: TRICYCLIC ANTIDEPRESSANTS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tricyclic antidepressants (for chronic low back pain)
Trial: 9566477
Drug: No pharmacological
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No pharmacological treatment (Control)
Trial: 7816261
Drug: Low-dose cyclosporin
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose cyclosporin A (CsA) treatment at a mean dose of 3.23 mg/kg/day for 12 months
Trial: 7816261
Drug: Low-dose cyclosporin
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose cyclosporin A (CsA) treatment
Trial: 2975147
Drug: Thiopental and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thiopental and NLA drugs
Trial: 28926296
Drug: Urokinase (100,000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Urokinase (100,000 IU, three doses, 12-hourly)
Trial: 23073171
Drug: Conjugated Linoleic
RxNorm normalized name: CONJUGATED LINOLEIC ACID
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conjugated Linoleic Acid (CLA) supplementation (3g daily for 30 days)
Trial: 23073171
Drug: Placebo (PLC)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (PLC) supplementation (3g daily for 30 days)
Trial: 21626077
Drug: Intravenous (IV)
RxNorm normalized name: intravenous (IV) infusion pump
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous (IV) nicardipine initiated within 3 hours of onset of ICH and continued for the next 24 hours
Trial: 30217640
Drug: Vasoactive medications
RxNorm normalized name: Vasoactive intestinal peptide
DrugBank: Vasoactive intestinal peptide (DB18634)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vasoactive medications
Trial: 16634837
Drug: B‐vitamins (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: B‐vitamins (50 mg thiaminhydrochlorid, 50 mg pyridoxine, and 0.05 mg cyanocobalamin), plus 5 mg folic acid daily for 6 weeks
Trial: 31069056
Drug: Alternative therapies
RxNorm normalized name: HERBS/ALTERNATIVE THERAPIES
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alternative therapies
Trial: 9663826
Drug: Intravenous standard
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous standard heparin (subcutaneous in two patients), adjusted to provide standard anticoagulant activity.
Trial: 9663826
Drug: Heparin (second
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heparin (second occasion during a relapse)
Trial: 9663826
Drug: Heparin (general
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heparin (general treatment)
Trial: 31924334
Drug: Nivolumab 3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nivolumab 3 mg/kg IV every 2 weeks until disease progression or intolerable toxicity
Trial: 23250818
Drug: Vitamin D3
RxNorm normalized name: Vitamin D3
DrugBank: Cholecalciferol (DB00169)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin D3 supplementation (50,000 IU weekly for 12 months)
Trial: 14519707
Drug: Estrogen plus
RxNorm normalized name: estrogens
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Estrogen plus progestin (conjugated equine estrogen, 0.625 mg/d, plus medroxyprogesterone acetate, 2.5 mg/d)
Trial: 10534147
Drug: Chinese medicinal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chinese medicinal herbs (seven pills containing a standardized preparation of 35 Chinese herbs, four daily doses for 6 months)
Trial: 7159001
Drug: Clindamycin-gentamycin combination
RxNorm normalized name: clindamycin, combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clindamycin-gentamycin combination
Trial: 25571338
Drug: Tizanidine (α2-adrenergic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tizanidine (α2-adrenergic agonist), administered over a 4-week program
Trial: 22748458
Drug: Bundle treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bundle treatment
Trial: 18195164
Drug: Low-carbohydrate diet
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-carbohydrate diet (20 g of carbohydrates)
Trial: 10792114
Drug: Misoprostol 100
RxNorm normalized name: MISOPROSTOL 100MCG TAB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Misoprostol 100 microg daily
Trial: 1734572
Drug: Epidural morphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epidural morphine sulfate (EPI)
Trial: 1734572
Drug: Intramuscular morphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular morphine sulfate (IM)
Trial: 1734572
Drug: Patient controlled
RxNorm normalized name: PATIENT CONTROLLED ANALGESIA VIAL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patient controlled morphine sulfate (PCA)
Trial: 6734037
Drug: Nalbuphine (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nalbuphine (30 mg)
Trial: 6734037
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of nalbuphine (30 mg) and acetaminophen (650 mg)
Trial: 29463159
Drug: 5% urea
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5% urea lotion
Trial: 27367745
Drug: Difluprednate 0.05%
RxNorm normalized name: DIFLUPREDNATE 0.05% EMULSION,OPH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Difluprednate 0.05% four times daily
Trial: 24677110
Drug: Prednisolone acetate
RxNorm normalized name: Prednisolone Acetate
DrugBank: Prednisolone acetate (DB15566)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Prednisolone acetate 1% eight times daily
Trial: 16050943
Drug: Pramlintide (0.1-1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pramlintide (0.1-1 mg daily or 0.1-0.8 mg four times a day for 5 or 6 days)
Trial: 16050943
Drug: Pramlintide (30,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pramlintide (30, 100 or 300 microg three times daily for 14 days)
Trial: 16050943
Drug: Pramlintide (various
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pramlintide (various doses as mentioned)
Trial: 14763223
Drug: Fixed combination
RxNorm normalized name: Progestogens and estrogens, fixed combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fixed combination of cinnarizine (20 mg) and dimenhydrinate (40 mg) (Arlevert [ARL])
Trial: 14763223
Drug: Betahistine dimesylate
RxNorm normalized name: betahistine dimesylate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Betahistine dimesylate (12 mg)
Trial: 14763223
Drug: Fixed combination
RxNorm normalized name: Progestogens and estrogens, fixed combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fixed combination of cinnarizine and dimenhydrinate (ARL)
Trial: 8952010
Drug: Vigabatrin 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vigabatrin 2 g/day
Trial: 7056952
Drug: Beclomethasone dipropionate
RxNorm normalized name: Beclomethasone Dipropionate
DrugBank: Beclomethasone dipropionate (DB00394)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beclomethasone dipropionate (BDP) at 1600 mg/day
Trial: 7056952
Drug: Fluocortin butylester
RxNorm normalized name: fluocortin
DrugBank: Fluocortin (DB13223)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluocortin butylester (FCB) used well in excess of its presumed therapeutic dose range
Trial: 19191674
Drug: T80/H25 fixed-dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: T80/H25 fixed-dose combination (FDC)